Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRGX Stock Forecast 2025-2026
$4.51
Current Price
$208.39M
Market Cap
Buy 0
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to CRGX Price Targets
+565.2%
To High Target of $30.00
+22.0%
To Median Target of $5.50
-18.0%
To Low Target of $3.70
CRGX Price Momentum
-2.0%
1 Week Change
+7.9%
1 Month Change
-75.9%
1 Year Change
-68.7%
Year-to-Date Change
-82.3%
From 52W High of $25.45
+50.3%
From 52W Low of $3.00
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching CARGO Therapeutics (CRGX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CRGX and similar high-potential opportunities.
Latest CRGX Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, CRGX has a neutral consensus with a median price target of $5.50 (ranging from $3.70 to $30.00). Currently trading at $4.51, the median forecast implies a 22.0% upside. This outlook is supported by 0 Buy, 5 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRGX Analyst Ratings
0
Buy
5
Hold
1
Sell
CRGX Price Target Range
Low
$3.70
Average
$5.50
High
$30.00
Current: $4.51
Latest CRGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 30, 2025 | Piper Sandler | Biren Amin | Neutral | Downgrade | $4.00 |
| Jan 30, 2025 | Chardan Capital | Geulah Livshits | Neutral | Downgrade | $0.00 |
| Jan 30, 2025 | HC Wainwright & Co. | Robert Burns | Neutral | Downgrade | $0.00 |
| Jan 30, 2025 | William Blair | Sami Corwin | Market Perform | Downgrade | $0.00 |
| Jan 30, 2025 | Jefferies | Michael Yee | Hold | Downgrade | $3.00 |
| Jan 30, 2025 | Truist Securities | Asthika Goonewardene | Hold | Downgrade | $7.00 |
| Jan 30, 2025 | JP Morgan | Brian Cheng | Underweight | Downgrade | $0.00 |
| Nov 26, 2024 | William Blair | Sami Corwin | Outperform | Initiates | $0.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $33.00 |
| Nov 13, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $28.00 |
| Aug 13, 2024 | Piper Sandler | Biren Amin | Overweight | Maintains | $34.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $33.00 |
| Jul 22, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Initiates | $33.00 |
| Jul 8, 2024 | Chardan Capital | Geulah Livshits | Buy | Initiates | $28.00 |
| Jun 27, 2024 | Piper Sandler | Biren Amin | Overweight | Initiates | $37.00 |
| May 16, 2024 | Truist Securities | Asthika Goonewardene | Buy | Reiterates | $32.00 |
| Mar 22, 2024 | Jefferies | Michael Yee | Buy | Maintains | $32.00 |
| Dec 5, 2023 | Truist Securities | Asthika Goonewardene | Buy | Initiates | $34.00 |
| Dec 5, 2023 | TD Cowen | Tyler Van Buren | Outperform | Initiates | $0.00 |
| Dec 5, 2023 | JP Morgan | Brian Cheng | Overweight | Initiates | $23.00 |
Cargo Therapeutics Inc. (CRGX) Competitors
The following stocks are similar to CARGO Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cargo Therapeutics Inc. (CRGX) Financial Data
Cargo Therapeutics Inc. has a market capitalization of $208.39M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -43.8%.
Valuation Metrics
Market Cap
$208.39M
Enterprise Value
$-102,581,824
P/E Ratio
0.0x
PEG Ratio
-1.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+163.5%
Current Ratio
13.8x
Debt/Equity
8.2x
ROE
-43.8%
ROA
-27.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cargo Therapeutics Inc. (CRGX) Business Model
About Cargo Therapeutics Inc.
What They Do
Develops novel cell therapies for cancer treatment.
Business Model
Cargo Therapeutics generates revenue by developing and commercializing advanced immunotherapy treatments, particularly chimeric antigen receptor (CAR) T-cell therapies. The company focuses on engineering T-cells to improve their effectiveness against various cancer types, aiming to provide innovative solutions where traditional therapies fall short.
Additional Information
As a biotechnology firm, Cargo Therapeutics is positioned at the forefront of personalized medicine, contributing significantly to the advancement of therapeutic options for life-threatening diseases. Their commitment to scientific innovation and addressing unmet medical needs underscores their potential impact in the healthcare sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
167
CEO
Mr. Anup Radhakrishnan
Country
United States
IPO Year
2023
Website
cargo-tx.comCargo Therapeutics Inc. (CRGX) Latest News & Analysis
Latest News
CARGO Therapeutics Provides Corporate Update
1 month ago
Quick Summary
CARGO Therapeutics has suspended development of CRG-023 and its allogeneic platform, reducing its workforce by 90%. The company had $368.1M in cash as of Dec 31, 2024, with Anup Radhakrishnan as interim CEO.
Why It Matters
CARGO Therapeutics' suspension of development and major workforce cuts signal financial distress, raising concerns about future viability and potential shareholder value erosion.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky is investigating CARGO Therapeutics (NASDAQ:CRGX) for potential federal securities law violations following the discontinuation of its Phase 2 clinical study of firi-cel for LBCL.
Why It Matters
The investigation into CARGO Therapeutics for potential securities law violations, combined with the discontinuation of a clinical study, may signal significant risks and impact stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky is investigating CARGO Therapeutics (NASDAQ:CRGX) for potential federal securities law violations following the discontinuation of its Phase 2 study for firi-cel on January 29, 2025.
Why It Matters
CARGO Therapeutics faces potential legal issues over federal securities laws following the discontinuation of a key clinical study, which may impact stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for investors of CARGO Therapeutics, Inc. (NASDAQ:CRGX). Interested parties should contact Danielle Peyton at the provided email or phone number.
Why It Matters
The investigation into CARGO Therapeutics may indicate potential legal issues, which could affect stock performance and investor confidence in the company.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
The Schall Law Firm is investigating CARGO Therapeutics (NASDAQ:CRGX) for potential securities law violations, including false statements affecting investors.
Why It Matters
The investigation into CARGO Therapeutics for potential securities law violations could signal financial instability or legal risks, affecting stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky is investigating CARGO Therapeutics (NASDAQ:CRGX) for potential federal securities law violations following its decision to discontinue a Phase 2 study of firi-cel for LBCL.
Why It Matters
The investigation into CARGO Therapeutics for potential securities law violations and the discontinuation of a key clinical study may signal financial instability and impact stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About CRGX Stock
What is Cargo Therapeutics Inc.'s (CRGX) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Cargo Therapeutics Inc. (CRGX) has a median price target of $5.50. The highest price target is $30.00 and the lowest is $3.70.
Is CRGX stock a good investment in 2025?
According to current analyst ratings, CRGX has 0 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $4.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRGX stock?
Wall Street analysts predict CRGX stock could reach $5.50 in the next 12 months. This represents a 22.0% increase from the current price of $4.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cargo Therapeutics Inc.'s business model?
Cargo Therapeutics generates revenue by developing and commercializing advanced immunotherapy treatments, particularly chimeric antigen receptor (CAR) T-cell therapies. The company focuses on engineering T-cells to improve their effectiveness against various cancer types, aiming to provide innovative solutions where traditional therapies fall short.
What is the highest forecasted price for CRGX Cargo Therapeutics Inc.?
The highest price target for CRGX is $30.00 from at , which represents a 565.2% increase from the current price of $4.51.
What is the lowest forecasted price for CRGX Cargo Therapeutics Inc.?
The lowest price target for CRGX is $3.70 from at , which represents a -18.0% decrease from the current price of $4.51.
What is the overall CRGX consensus from analysts for Cargo Therapeutics Inc.?
The overall analyst consensus for CRGX is neutral. Out of 8 Wall Street analysts, 0 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $5.50.
How accurate are CRGX stock price projections?
Stock price projections, including those for Cargo Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 1:25 PM UTC